In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including: Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCC Overview of the Latest Data for the Combination of TACE With Immunotherapy (eg, EMERALD-1 Study of TACE and Durvalumab ± Bevacizumab for Unresectable HCC; and LEAP-012 Study of TACE + Lenvatinib + Pembrolizumab) Latest Clinical Data and Updates for Systemic Therapy in Patients With High-Risk Early HCC Program faculty: Joseph W. Franses, MD, PhD Assistant Professor of Medicine Section of Hematology-Oncology University of Chicago Chicago, Illinois Neehar Parikh, MD, MS Associate Professor Li Ka Shing Research Professor of Hepatology Clinical Director of Hepatology Medical Director, Liver Tumor Program Division of Gastroenterology & Hepatology University of Michigan Ann Arbor, Michigan Mark Yarchoan, MD Associate Professor Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Baltimore, Maryland Resources: To access the resources associated with this podcast discussion, please visit the program page to access a recording from a live webinar and a frequently-asked questions commentary on this topic. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
